Back

Incentivizing Narrow-Spectrum Antibiotics Development with Refunding

2020-07-15 health economics Title + abstract only
View on medRxiv
Show abstract

The rapid rise of antibiotic resistance is a serious threat to global public health. Without further incentives, pharmaceutical companies have little interest in developing antibiotics, since the success probability is low and development costs are huge. The situation is exacerbated by the "antibiotics dilemma": Developing narrow-spectrum antibiotics against resistant bacteria is most beneficial for society, but least attractive for companies since their usage is more limited than for broad-spec...

Predicted journal destinations